Aviat Networks (AVNW) was targeted by a short report published Apr 4, 2026 alleging the company is not generating reported earnings; investors should demand reconciliations and auditor clarity.

Imagine this: Jane is born. Ah, marvel the miracle of birth! Tears of joy in the eyes of the parent(s). Family members start snapping the first photos of the baby. A quick update to social media: ‘The latest addition to the family has arrived! Say hello to little Jane! ❤️' Likes and loves are pouring in by t...

The idea behind the development of the 3Cs of online risk was to disaggregate specific risks, with their different causes and consequences, and broaden the public agenda beyond the then predominant focus on pornography, grooming and cyberbullying.

Resilience has become somewhat of a buzzword in a variety of contexts – from materials to minds. While personal resilience refers to the capacity to maintain or regain psychological wellbeing in the face of challenges, …

Investing.com -- iRhythm Technologies (NASDAQ:IRTC) stock fell 2% Monday morning after the company was targeted in a short report from Spruce Point Capital Management. The investment firm issued a detailed report titled "Investor Complacency is Off the Charts," estimating that iRhythm shares face 40%-70% potential long-term downside to approximately $43-$94 per share. Spruce Point cited concerns about the medical technology company’s cardiac monitoring products and management credibility. According to the report, Spruce Point found evidence suggesting the Department of Justice is investigating a possible cover-up by iRhythm management related to potentially fatal product flaws. The firm highlighted FDA findings that iRhythm products put patients’ lives at risk, including issues with the Zio AT device that allegedly ceased transmitting patient data above certain limits. The short seller also questioned iRhythm’s growth potential in the asymptomatic patient market, which the company has promoted as a significant opportunity. Spruce Point’s survey of 100 cardiologists indicated that testing asymptomatic patients "has not been adopted as a standard of care by any credible organization." The report further claimed that iRhythm’s products are undifferentiated in a market facing increasing competition, including from consumer devices like Apple (NASDAQ:AAPL) and Samsung (KS:005930) smartwatches that can detect arrhythmias with "near-comparable sensitivity." Spruce Point argued that iRhythm’s current valuation of approximately $5.4 billion, representing 7x 2026 estimated revenue, is unjustified for what it described as a "niche and commoditized single product company with a history of poor profitability." This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With IRTC making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed IRTC alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including IRTC, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is IRTC poised for similar growth? Don't miss the opportunity to find out.